Abstract
Multiple myeloma (MM), like other hematological malignancies, has both normal and clonal neoplastic cells coresiding in the bone marrow. To perform interphase fluorescent in situ hybridization (FISH) analysis accurately, for the detection of clonal chromosome abnormalities, it is crucial to restrict the analysis to the tumoral cells. The correct detection of these abnormalities may have diagnostic, prognostic, and therapeutic implications. Our laboratory has developed a clone-specific cytoplasmic immunoglobulin (cIg) staining method coupled with FISH (cIg-FISH) for the study of plasma cell (PC) neoplasms. An unlimited combination of DNA probes can be used with this technique to examine the genetic changes that frequently occur in patients with these diseases, one of which is abnormalities of chromosome 13. Using the two techniques simultaneously (i.e., cIg-FISH), we have demonstrated that approx 50% of patients with MM have abnormalities of chromosome 13, mostly monosomy, and when present involving the majority of the cells. In this chapter, we present the technical methodology for detecting chromosome abnormalities and how to restrict the analysis to the clonal PCs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dewald G. W., Kyle R. A., Hicks G. A., and Greipp P. R. (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66, 380ā390.
Sawyer J. R., Waldron J. A., Jagannath S., and Barlogie B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet. Cytogenet. 82, 41ā49.
Smadja N. V., Fruchart C., Isnard F., et al. (1998) Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 12, 960ā969.
Drach J., Schuster J., Nowotny H., et al. (1995) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 55, 3854ā3859.
Zandecki M., Lai J. L., and Facon T. (1996) Multiple myeloma: almost all patients are cytogenetically abnormal. Br. J. Haematol. 94, 217ā227.
Fonseca R., Ahmann G. J., Juneau A. L., et al. (1997) Cytogenetic abnormalities in multiple myeloma and related plasma cell disorders: a comparison of conventional cytogenetic analysis to fluorescent in-situ hybridization with simultaneous cytoplasmic immunoglobulin staining (meeting abstract). Blood 90, 1558a, p1349.
Fonseca R., Oken M., Harrington D., et al. (2001) Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia 15, 981ā986.
Zojer N., Konigsberg R., Ackerman J., et al. (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95, 1925ā1930.
Facon T., Avet-Loiseau H., Guillerm G., et al. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97, 1566ā1571.
Avet-Loiseau H., Daviet A., Saunier S., and Bataille R. (2000) Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br. J. Haematol. 111, 1116ā1117.
Fonseca R., Harrington D., Oken M., et al. (2002) Biologic and prognostic significance of interphase FISH detection of chromosome 13 abnormalities (Ī13) in multiple myeloma: an Eastern Cooperative Oncology Group (ECOG) study. Cancer Res. 62, 715ā720.
Desikan R., Barlogie B., Sawyer J., et al. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95, 4008ā4010.
Ahmann G. J., Jalal S. M., Juneau A. L., et al. (1998) A novel three-color, clonespecific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet. Cytogenet. 101, 7ā11.
Fonseca R. and Ahmann G. J. (2003) Assays for neoplastic cell enrichment in bone marrow samples, in Methods in Molecular Medicine, Vol. 85, Novel Anticancer Drug Protocols (Buolamwini J. and Adjei A., eds.), Humana, Totowa, NJ, pp. 333ā342.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2005 Humana Press Inc.
About this protocol
Cite this protocol
VanWier, S., Fonseca, R. (2005). Detection of Chromosome 13 Deletions by Fluorescent In Situ Hybridization. In: Brown, R.D., Ho, P.J. (eds) Multiple Myeloma. Methods in Molecular Medicineā¢, vol 113. Humana Press. https://doi.org/10.1385/1-59259-916-8:59
Download citation
DOI: https://doi.org/10.1385/1-59259-916-8:59
Publisher Name: Humana Press
Print ISBN: 978-1-58829-392-3
Online ISBN: 978-1-59259-916-5
eBook Packages: Springer Protocols